Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)
Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)
This study aims to establish the safety, tolerability, and efficacy of Vytorin (R) (Ezetimibe
 + Simvastatin) (SCH 465981) on a select population of Filipinos with hypercholesterolemia.
Inclusion Criteria:

 -  Outpatient men or women, age 18 years and above

 -  Patients with primary (heterozygous familial and non-familial) hypercholesterolemia

 Exclusion Criteria:

 -  Known hypersensitivity to Ezetimibe and Simvastatin

 -  Moderate to severe hepatic insufficiency

 -  Persistent elevation of serum transaminase levels of more than 1.5 times the upper
 limit of normal

 -  Pregnancy or lactation

 -  Concomitant intake of bile acid sequestrants (resins), nicotinic acid (niacin), fibric
 acid (fibrates), or cyclosporine